Repare Therapeutics’ Post

Atossa Therapeutics announces an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Previous in silico and preclinical research determined a strong, clinically relevant, anti-tumor effect when combining the two therapies. “The work we are doing with Weill Cornell is designed to validate the in silico modeling in well-established cell culture models of breast cancer. Once we have this data, we expect to move quickly into a clinical study investigating a (Z)-endoxifen / ADC combination in patients with late-line metastatic breast cancer,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. Learn more: https://lnkd.in/ekad_hWY #clinicaltrial #breastcancer, https://lnkd.in/ev6gadb7

#2024AACR poster is now up 💡 Check out the poster on our website! https://lnkd.in/e_j4azc9 “LP-284 didn’t exist when Lantern went public in 2020, and less than three years later, with just $3 million in development costs, the company is manufacturing the drug, and the first patients have already been dosed.” D Magazine. Swipe right to learn more about our drug candidate LP-284, currently in Phase 1 #clinicaltrial for Non-Hodgkin's lymphomas (#NHL) and solid tumors. Leveraging #ArtificialIntelligence, #MachineLearning, and  #genomics, Lantern Pharma Inc. (Nasdaq: LTRN) is working towards transforming the cost, pace, and timeline of oncology drug discovery and development. AACR Journals American Association for Cancer Research #Oncology #OncologyResearch #CancerResearch #AcademicPosters #Posterpresentation #ClinicalTrials

Discover the latest insights in cancer research, focusing on the vital role of selecting the right mouse models in oncology drug development, in this informative article by BioBuzz featuring Noble Life Sciences.

One of the biggest challenges for cancer therapeutics, is the targeting of solid tumors. Poor tumor tissue penetration and the heterogeneous distribution have limited the clinical efficacy of therapeutic antibodies. Striking advances in bispecific/multispecific antibodies, T cell engagers and antibody-drug conjugates are now leading the way in oncology discovery, with new strategies to target solid tumors and the tumor microenvironment. This year’s #PEGS23 will present the latest and hottest in #antibodytherapeutics for #cancer, highlight the #emergingtargets, as well as showcase the exciting resurgence of #antibodydrugconjugates as a hot therapeutic modality. Check out our 3 conferences in the #oncology stream that are driving #innovativetherapies toward #clinicalsuccess. https://lnkd.in/etSdyvKa Antibodies for Cancer Therapy Emerging Targets for Oncology and Beyond Driving Clinical Success in Antibody Drug Conjugates

Today we announce an exclusive global licensing deal with MENARINI Group and Stemline Therapeutics to develop and commercialize a small molecule KAT6 inhibitor designed using Insilico’s generative AI platform for breast cancer and other oncology indications. ● KAT6 is an emerging cancer target. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. ● The molecule has demonstrated strong preclinical activity. Insilico Medicine presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December. ● The agreement includes upfront and milestone payments with a combined potential value of over $500m and up to double digit sales royalties. Read more from Gabrielle Masson in Fierce Biotech (link in comments). #ai #genai #cancer #breastcancer #deal #drugdiscovery

In less than 8 months, the EU #HTA Regulation will become a reality: all new #cancer #medicines and advanced therapy medicinal products will be jointly assessed at the EU level. A recent report commissioned by the EFPIA Oncology Platform simulated the new joint clinical assessment on 3 cancer medicines that were approved in recent years. It shows that the proposed methods do not always fit the specificities of medicines for cancer and novel therapies that use genes, tissues and cells. If applied from 2025, this approach would hamper access to some of the most cutting-edge products in the research pipeline. Join us for a discussion on how we can work together to ensure that EU HTA can facilitate faster access for patients together with: - Antonella Cardone, CEO, Cancer Patients Europe - Robin Doeswijk, Head of European Affairs, European Hematology Association - Tanja Podkonjak, Head of Access Intelligence and Readiness, Takeda 🗓 4 June 2024 🕛 12:30-14:00 📍 Online ✏ Register here: https://lnkd.in/g4b8Nx-P

During my college and med school years, the #HumanGenomeProject was in full swing. As a self-proclaimed nerd, I was thrilled by the potential of sequencing the human genome. Last week, I felt that same excitement at an internal meeting discussing the Cell Surfaceome. This initiative holds immense promise for oncology drug development, particularly in the use of radioligands, antibody-drug conjugates (ADCs), and other innovative therapies. For those interested in learning more, this article is a great place to start: Elucidating the Cell Surfaceome to Accelerate Oncology Drug Development. #RLT #AACR #DrugDevelopmemt #Oncology #Cancer #Surfaceome Novartis https://lnkd.in/gvaUeDst

#ESMOBreast24: last hours to register at a preferential rate! See what Suzette Delaloge , Evandro de Azambuja, Erika Hamilton and others are saying about this event. 👉Register by 17 April and save 🔗https://ow.ly/T12V50Rg7Cb High quality scientific and educational sessions, featuring translational research, new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications in the clinical setting: During this event, you will be able to: ➡️Understand recent developments in novel diagnostics, biomarkers and treatments in breast cancer ➡️ Be updated on the rapid development of novel antibody drug conjugates #BreastCancer ➡️ Gain insights on new strategies for Luminal, HER2 positive, HER2-low and triple negative breast cancer ➡️ Understand special considerations for different subgroups of patients with breast cancer

Check out this article from Nature reviews clinical oncology - “Lung Cancer in Patients Who Have Never Smoked — An Emerging Disease” The article delves into the molecular and genomic characteristics of LCINS, offering unique perspectives on diagnostic and treatment approaches. Understanding the distinct features of this disease is crucial for shaping future screening efforts and treatment decisions. Phase II Harmonic™ trial (NCT05456256) for our drug candidate LP-300, tailored specifically for non-small cell lung cancer (#NSCLC) patients who are #neversmokers. To find out further details about the trial, visit www.harmonictrial.com. Check out the full article here https://bit.ly/3tPcz9s Learn more about Lantern Pharma - www.lanternpharma.com #LungCancer #LCINS #HarmonicTrial #NSCLC #ClinicalTrials

Research & Innovation at Georgetown ✨ Dr. Samir Khleif, an immunologist and professor of oncology at Georgetown University’s Lombardi Comprehensive Cancer Center, and his research group made a groundbreaking discovery in understanding immunotherapy resistance. By focusing on why immunotherapy sometimes fails, Dr. Khleif's research has led to innovative strategies overcoming resistance in cancers like ovarian, lung, and pancreatic. Key Highlights: 💡 Discovery of new T-cell dysfunction leading to immunotherapy resistance. 🔬 Two clinical trials are underway for ovarian and lung/pancreatic cancers. 🤝 Unique collaboration with big pharmaceutical companies for a comprehensive treatment approach. Learn more about this medical breakthrough and how Georgetown University is fostering improvements in cancer treatment: [https://lnkd.in/emGRg9Xq] #GeorgetownInnovation #Research #CancerResearch #Immunotherapy